Answers are grounded in this paper and cite their sources.
Several lower-intensity therapies for isocitrate dehydrogenase 1/2 ( IDH1/2 )-mutated AML are available (Supplemental Table 1 ), including small molecule inhibitors of mutant IDH1 (ivosidenib and olutasidenib) and IDH2 (enasidenib), used alone or in combination with broader anti-leukemic agents. While not molecularly targeted therapy per se, venetoclax-based therapy has preferential activity in IDH1/2 -mutated disease [ 1 , 2 , 3 ]. Given uncertainty surrounding the optimal sequence of these agents, we investigated the quality and duration of responses to venetoclax and hypomethylating agent (VEN + HMA) combinations in IDH1/2 -mutated AML. We additionally characterize response patterns in a subset of these patients who were consecutively treated (either directly before or after VEN + HMA) with IDH inhibitor (IDHi)-based regimens.
No takes yet. Share an insight, caveat, or question.
Hammond et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: